Highest-materiality recent filing
KORU Medical Q1 revenue $11.8M (+22% YoY); net loss improves to $0.8M; FY guidance reiterated
Net revenue $11.8M, up 22% YoY; domestic core +11.7%, international core +35.2%, pharma services +166%.
CEO Linda Tharby to retire June 2026; Adam Kalbermatten named successor
Tharby retires as CEO effective June 30, 2026; will serve as advisory employee through Dec 31, 2026.
KORU Medical reports 22% FY2025 revenue growth; positive adjusted EBITDA; initiates FY2026 guidance
Q4 2025 net revenue $10.9M (+23% YoY); FY2025 net revenue $41.1M (+22% YoY).
Preliminary Q4 2025 net revenue $10.9M, up 23% YoY; full year net revenue $41.1M, up 22% YoY.
KORU Medical Q3 revenue $10.4M (+27% YoY), raises full-year guidance
Q3 net revenues $10.4M, up 27% YoY; core business (domestic + international) $9.8M, up 30%.
KORU Medical Q2 revenue up 21% to record $10.2M; raises FY 2025 revenue guidance
Q2 2025 net revenue of $10.2 million, +21% YoY; Core revenue $9.3M (+19%), PST $0.9M (+42%).
KORU Medical reports record Q1 revenue of $9.6M, up 18% YoY; raises FY2025 guidance
Core revenue (Domestic + International) grew 21% YoY to $9.4M; International up 35.6%.
KORU Medical reports record Q4 revenue of $8.8M (+23% YoY); issues 2025 guidance $38-39M
Q4 net revenue $8.8M (+23% YoY); full year $33.6M (+18% YoY).
KORU Medical reports record Q4 revenue $8.9M (+23% YoY); positive cash flow in Q4
Preliminary full-year 2024 net revenue of $33.7M, up 18% YoY; Q4 revenue $8.9M, up 23% YoY.
KORU Medical Q3 revenue $8.2M (+17% YoY); raises FY 2024 guidance
Q3 net revenue $8.2M, up 17% YoY; gross margin 63.4%, up 140 bps from 62.0%.
KORU Medical Q2 revenue record $8.4M, up 22%; raises FY2024 guidance
Q2 net revenues of $8.4M, a 22% YoY increase; core business grew 20% driven by SCIg market growth and share gains.
KORU Medical Q1 revenue up 11% to $8.2M; gross margin expands 620bps to 62.3%
Net revenues of $8.2M, +10.9% YoY; Core business grew 13.6%, driven by 63% International increase.
KORU Medical wins EU notified body appeal, CE certification continues uninterrupted
BSI had recommended against continued certification after March 2024 audit nonconformance.
KORU Medical reports Q4 rev $7.2M, FY net loss $13.7M; guides 2024 rev $31.2-32.2M
Q4 net revenues $7.2M (-2% YoY); gross margin improved to 60.3% (+470bps).
On April 3, 2025, Kenneth Miller resigned his employment and position as Chief Commercial Officer of KORU Medical Systems, Inc. (the “Company”), effective immediately, to pursue a Chief Executive Officer role at an organization that does not compete with the Company.
On July 18, 2024, the Company’s Board of Directors eliminated the position of Chief Technology Officer, currently held by Brian Case, effective as of September 16, 2024. Mr. Case’s employment with the Company will terminate concurrently with elimination of that position.
Max materiality 0.75 · Median 0.60 · Most common event earnings